← All countries · Europe
96%
MCV1
2025 · WHO/UNICEF estimate
93%
DTP3
2025 · WHO/UNICEF estimate
98%
IPV complete
2025 · WHO/UNICEF estimate
98%
HepB3
2025 · WHO/UNICEF estimate
398
Measles cases
2025 reported
813
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | —% · Administrative (country-reported) | — | too few points | no data |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | 97.8% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 93%2025 · WHO/UNICEF estimate | 93.6% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 97.8% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 98%2025 · WHO/UNICEF estimate | 97.8% | C · weak | |
| MCV1First dose of measles-containing vaccine | 96%2025 · WHO/UNICEF estimate | 96.0% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 92%2025 · WHO/UNICEF estimate | 92.1% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 96%2025 · WHO/UNICEF estimate | 96.0% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 98%2025 · WHO/UNICEF estimate | 93.6% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 97.2%2017 · Administrative (country-reported) | 97.2% | too few points | D · poor |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 98%2025 · WHO/UNICEF estimate | 93.5% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 97.5%2020 · Administrative (country-reported) | 97.5% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 89%2025 · WHO/UNICEF estimate | 94.7% | B · good | |
| RotaCRotavirus vaccine, complete series | 76%2025 · WHO/UNICEF estimate | 76.5% | C · weak | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 91%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 91%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 89%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 3982025 | 8.3per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 12025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 2,2412025 | 46.8per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 8132025 | 17per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 32025 | 0.1per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 32025 | 0.1per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 4052025 | 8.5per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 702025 | 1.5per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (74 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| CHOLERACholera vaccine | 1 | Travellers | Travellers | |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M4 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M11 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | Y6 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Risk groups | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M15 | General/routine · SUBNATIONAL | Subnationally in one region and two cities (Catalonia at 15 months and 6 years, Ceuta and Melilla at 15 months and 24 months) |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Risk groups (all Regions) | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 2 | M24-Y6 | General/routine · SUBNATIONAL | Subnationally in one region and two cities (Catalonia at 15 months and 6 years, Ceuta and Melilla at 15 months and 24 months) |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Health workers | Health and care workers | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Risk groups | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | Administered only for newborns of mothers with AgHBs+ |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Risk group(s) | Specific children who weren’t immunized in their childhood (migrants and other) | |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y12 | HPV administered to females and males | 2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too- |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | >Y26 | Risk group(s) | Risk groups (all regions) |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | +M6 | HPV administered to females and males | 2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too- |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | +M1-M2 | Risk group(s) | Risk groups (all regions) |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 3 | +M6 | Risk group(s) | Risk groups (all regions) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y12 | HPV administered to females and males | 2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) and 4 and 9 valent vaccines administered for males |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M6 | HPV administered to females and males | 2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) and 4 and 9 valent vaccines administered for males |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y12 | HPV administered to females and males | 2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too- |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | >Y26 | Risk group(s) | Risk groups (all regions) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV administered to females and males | 2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too- |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M1-M2 | Risk group(s) | Risk groups (all regions) |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 3 | +M6 | Risk group(s) | Risk groups (all regions) |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y60 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-M59 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Travellers | Travellers | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 1 | Travellers | Travellers | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M4 | General/routine · SUBNATIONAL | In some regions, MenACWY-135_conj is administered instead of the first or/and second dose of MenC_conj at M4/M12 |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | M12 | General/routine · SUBNATIONAL | In some regions, MenACWY-135_conj is administered instead of the first or/and second dose of MenC_conj at M4/M12 |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 3 | Y12 | General/routine | |
| MEN_BMeningococcal B vaccine | 1 | M2 | General/routine | Men B vaccines were included in the 2023 schedule for enfants, with a deadline for incorporation for all regions during 2023 and until the end of 2024. |
| MEN_BMeningococcal B vaccine | 1 | Risk group(s) | Recommended to high-risk individuals: properdin or complement deficiency, multiple episodes of invasive meningococcal disease, specific laboratory personnel, or severe splenic dysfunction. | |
| MEN_BMeningococcal B vaccine | 2 | M4 | General/routine | Men B vaccines were included in the 2023 schedule for enfants, with a deadline for incorporation for all regions during 2023 and until the end of 2024. |
| MEN_BMeningococcal B vaccine | 3 | M12 | General/routine | Men B vaccines were included in the 2023 schedule for enfants, with a deadline for incorporation for all regions during 2023 and until the end of 2024. |
| MEN_C_CONJMeningococcal C conjugate vaccine | 1 | M4 | General/routine | In some regions, MenACWY-135_conj is administered instead of the first or/and second dose of MenC_conj at M4/M12 |
| MEN_C_CONJMeningococcal C conjugate vaccine | 2 | M12 | General/routine | In some regions, MenACWY-135_conj is administered instead of the first or/and second dose of MenC_conj at M4/M12 |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | Some regions administer MMRV instead of MMR and monovalent varicella only for the second dose. |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y3-Y4 | General/routine · SUBNATIONAL | Some regions administer MMRV instead of MMR and monovalent varicella only for the second dose. |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | Y3-Y4 | General/routine · SUBNATIONAL | Some regions administer MMRV instead of MMR and monovalent varicella only for the second dose. |
| MPOXMpox (monkeypox) vaccine | 1 | >Y18 | Risk group(s) | Risk groups (all regions) - people with riskier sexual practices and people with occupational risks who can not guarantee individual protection |
| MPOXMpox (monkeypox) vaccine | 2 | +M1 | Risk group(s) | Risk groups (all regions) - people with riskier sexual practices and people with occupational risks who can not guarantee individual protection |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | M2 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 2 | M4 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 3 | M11 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | >Y64 | Adults | |
| RABIESRabies vaccine | 1 | Travellers | Travellers | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | >W6 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | M6 only for RotaTeq |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | B | General/routine | First dose recommended for all newborns during the season. In preterm infants and infants at risk of severe RSV disease, one dose is recommended before the start of each season before 24 months of age. |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Risk group(s) | First dose recommended for all newborns during the season. In preterm infants and infants at risk of severe RSV disease, one dose is recommended before the start of each season before 24 months of age. | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Health workers | Certain healthcare workers | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Pregnant women | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >=Y65 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Risk group(s) | Wound prophylaxis, adults without vaccination history | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | Y14 | General/routine | |
| TYPHOID_CONJTyphoid conjugate vaccine | 1 | Travellers | Travellers | |
| TYPHOID_PSTyphoid polysaccharide vaccine | 1 | Travellers | Travellers | |
| VARICELLAVaricella vaccine | 1 | M15 | General/routine | Some regions administer MMRV instead of MMR and monovalent varicella only for the second dose. |
| VARICELLAVaricella vaccine | 2 | Y3-Y4 | General/routine · SUBNATIONAL | Some regions administer MMRV instead of MMR and monovalent varicella only for the second dose. |
| YFYF (Yellow fever) vaccine | 1 | Travellers | travellers only | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Y65-Y80 | Adults | 65 years old; 2nd dose administered +6 months at lease |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | >=Y60 | Risk group(s) · SUBNATIONAL | For specific risk groups |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M6 | Adults | 65 years old; 2nd dose administered +6 months at lease |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.